Germany · Delayed Price · Currency is EUR CStone Pharmaceuticals Statistics
Total Valuation
FRA:PH4 has a market cap or net worth of EUR 931.81 million. The enterprise value is 895.66 million.
| Market Cap | 931.81M |
| Enterprise Value | 895.66M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.47B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.61% |
| Shares Change (QoQ) | +2.92% |
| Owned by Insiders (%) | 1.53% |
| Owned by Institutions (%) | 12.86% |
| Float | 1.07B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 38.72 |
| PB Ratio | 24.88 |
| P/TBV Ratio | 49.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.98 |
| EV / Sales | 36.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 1.24.
| Current Ratio | 1.44 |
| Quick Ratio | 1.20 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.87 |
Financial Efficiency
Return on equity (ROE) is -96.36% and return on invested capital (ROIC) is -30.56%.
| Return on Equity (ROE) | -96.36% |
| Return on Assets (ROA) | -16.93% |
| Return on Invested Capital (ROIC) | -30.56% |
| Return on Capital Employed (ROCE) | -65.16% |
| Revenue Per Employee | 183,728 |
| Profits Per Employee | -342,148 |
| Employee Count | 135 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +159.84% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +159.84% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 0.57 |
| Relative Strength Index (RSI) | 42.81 |
| Average Volume (20 Days) | 278 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:PH4 had revenue of EUR 24.07 million and -44.82 million in losses. Loss per share was -0.03.
| Revenue | 24.07M |
| Gross Profit | -2.93M |
| Operating Income | -43.84M |
| Pretax Income | -44.82M |
| Net Income | -44.82M |
| EBITDA | -42.35M |
| EBIT | -43.84M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 82.03 million in cash and 46.52 million in debt, giving a net cash position of 35.51 million.
| Cash & Cash Equivalents | 82.03M |
| Total Debt | 46.52M |
| Net Cash | 35.51M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 37.45M |
| Book Value Per Share | 0.03 |
| Working Capital | 32.77M |
Cash Flow
| Operating Cash Flow | -51.15M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -12.18%, with operating and profit margins of -182.16% and -186.23%.
| Gross Margin | -12.18% |
| Operating Margin | -182.16% |
| Pretax Margin | -186.23% |
| Profit Margin | -186.23% |
| EBITDA Margin | -175.96% |
| EBIT Margin | -182.16% |
| FCF Margin | n/a |
Dividends & Yields
FRA:PH4 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.61% |
| Shareholder Yield | -1.61% |
| Earnings Yield | -4.81% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:PH4 has an Altman Z-Score of -9.6 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.6 |
| Piotroski F-Score | 1 |